Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 16/20 | 0.76 |
| ▸ | TP53 | P04637 | 4/20 | 0.76 |
| ▸ | THRB | P10828 | 2/20 | 0.76 |
| ▸ | PPARG | P37231 | 1/20 | 0.71 |
| ▸ | POLB | P06746 | 1/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30402758 | 0.91 | MAPT (0.83) | MAPTTP53THRBPOLBSMN1; SMN2 | |
| SCHEMBL17544319 | 0.91 | MAPT (0.83) | MAPTTP53THRBPOLBSMN1; SMN2 | |
| SCHEMBL27188271 | 0.83 | PPARG (1.00) | MAPTTP53PPARGPOLBSMN1; SMN2 | |
| SCHEMBL30402949 | 0.82 | MAPT (1.00) | MAPTTP53THRBRXFP1PTGS2 | |
| SCHEMBL2244624 | 0.82 | MAPT (1.00) | MAPTTP53THRBRXFP1PTGS2 | |
| SCHEMBL27188316 | 0.80 | PPARG (0.77) | MAPTTP53THRBPPARGPOLB | |
| SCHEMBL14758401 | 0.80 | MAPT (0.86) | MAPTTP53THRBSMN1; SMN2RXFP1 | |
| SCHEMBL2247470 | 0.79 | MAPT (0.89) | MAPTTP53THRBPOLBSMN1; SMN2 | |
| SCHEMBL16217094 | 0.78 | MAPT (0.92) | MAPTTP53THRBPOLBRXFP1 | |
| SCHEMBL2244186 | 0.78 | MAPT (0.92) | MAPTTP53THRBPOLBRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170283436-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | EVOTEC (UK) LTD. (GB) | 2017-10-05 | — | — | US | disclosed |
| US-20170283436-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | EVOTEC (UK) LTD. (GB) | 2017-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170283436-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | HTT, HYPK, FABP7 | MAPT 7/4885TP53 743/4885THRB 2432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.